Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Current Liabilities: 2018-2025

  • China SXT Pharmaceuticals' Total Current Liabilities fell 61.94% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 61.94%. This contributed to the annual value of $6.0 million for FY2025, which is 32.46% down from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Total Current Liabilities of $6.0 million as of Q3 2025, which was down 0.84% from $6.0 million recorded in Q1 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Total Current Liabilities peaked at $18.6 million during Q1 2021, and registered a low of $6.0 million during Q3 2025.
  • For the 3-year period, China SXT Pharmaceuticals' Total Current Liabilities averaged around $10.0 million, with its median value being $9.1 million (2023).
  • Per our database at Business Quant, China SXT Pharmaceuticals' Total Current Liabilities skyrocketed by 70.26% in 2024 and then plummeted by 61.94% in 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Total Current Liabilities (Quarterly) stood at $8.9 million in 2021, then dropped by 17.87% to $7.3 million in 2022, then grew by 26.17% to $9.2 million in 2023, then soared by 70.26% to $15.7 million in 2024, then plummeted by 61.94% to $6.0 million in 2025.
  • Its Total Current Liabilities was $6.0 million in Q3 2025, compared to $6.0 million in Q1 2025 and $15.7 million in Q3 2024.